Bridgeway Capital Management’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Bridgeway Capital Management’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-36,600	Closed	-$139K	–	1429
2019 Q3	$139K	Buy	+36,600	New	+$132K	﹤0.01%	1220
2018 Q4	–	Sell	-19,868	Closed	-$392K	–	1506
2018 Q3	$392K	Hold	19,868	–	–	﹤0.01%	1196
2018 Q2	$631K	Buy	19,868 +12,020	+153%	+$433K	0.01%	1059
2018 Q1	$290K	Sell	7,848 -7,780	-50%	-$512K	﹤0.01%	1212
2017 Q4	$1.24M	Buy	+15,628	New	+$1.16M	0.01%	761

Other funds holding MLNT

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CCM

Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Bridgeway Capital Management's MLNT Position: Q4 2019 in Review

Bridgeway Capital Management sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q4 2019, closing a stake of 36,600 shares — an estimated $139K sold.

Bridgeway Capital Management first reported a position in MLNT in Q4 2017 and held it in 5 quarters. The position peaked at $1.24M in Q4 2017. 37 funds tracked by Wall St. Rank hold MLNT as of Q4 2019.

Bridgeway Capital Management reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Bridgeway Capital Management sold 36,600 Melinta Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $139K.
Bridgeway Capital Management first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 5 quarters.
Bridgeway Capital Management's Melinta Therapeutics, Inc. Common Stock position peaked at $1.24M in Q4 2017.
37 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Bridgeway Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.